[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636983":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":35,"centralContacts":39,"locations":45,"responsibleParty":88,"collaborators":92,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":98,"sex":104,"minAge":105,"maxAge":106,"enrollmentInfo":107,"targetDuration":24,"studyType":110,"phases":111,"briefSummary":113,"conditions":114,"keywords":117,"overallStatus":47,"whyStopped":24,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":127,"completionDateStruct":128,"leadSponsor":130,"locationsCount":131},{"fullName":5,"class":6},"University of Iowa","OTHER",[8,14,20],{"label":9,"type":10,"description":11,"interventionNames":12},"DELFI FirstLook Lung Cancer Screening Blood Test","EXPERIMENTAL","Participants may choose to receive the DELFI Diagnostics FirstLook Lung test, a blood-based screening test designed to support early detection of lung cancer. The test analyzes patterns in cell-free DNA fragments using whole-genome sequencing and machine-learning techniques. Designed to augment traditional low-dose CT screening, it offers a minimally invasive and accessible option for early lung cancer detection.\n\nIf a participant elects to receive this test, a blood sample will be collected at a study clinic and sent to a DELFI Diagnostics lab without any personal identifying health information attached. After processing, results are returned to the study team. Participants will be notified if results are not elevated, in which case repeating the test in one year is recommended. If results are elevated, study staff will recommend follow-up screening with a low-dose CT scan from local clinic for further evaluation.\n\nBoth the blood test and CT will be provided by the study at no cost.",[13],"Diagnostic Test: DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test",{"label":15,"type":16,"description":17,"interventionNames":18},"Low-Dose CT","ACTIVE_COMPARATOR","Participants can choose to follow current US Preventive Services Task Force recommendations of a low-dose CT scan ordered through their primary care physician.",[19],"Diagnostic Test: Low-Does CT Scan",{"label":21,"type":22,"description":23,"interventionNames":24},"No lung cancer screening","NO_INTERVENTION","Participants chose to not participate in lung cancer screening. Annually, participants will be informed about lung cancer screening options and given the opportunity to participate in one of the screening options. Participants will have the ability to change their mind and choose one of the lung cancer screening options in between their annual screening discussion.",null,[26,31],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":24},"DIAGNOSTIC_TEST","DELFI Diagnostics FirstLook Lung Cancer Screening Blood Test","A participant can choose to receive this test. This is done by receiving a blood draw. The blood sample is sent to the DELFI Diagnositics lab without any personal health information attached. Results will be relayed to the participant as either \"elevated\" or \"not elevated\". IF the result is \"elevated\" the participant will be recommended to receive a low-dose CT scan.",[9],{"type":27,"name":32,"description":33,"armGroupLabels":34,"otherNames":24},"Low-Does CT Scan","If a participant chooses this arm, the participant will request their primary care physician to order them a low-dose CT scan as part of the USPSTF standards for lung cancer screening. Participants will be asked to fax the results of those scans to the study.",[15],[36],{"name":37,"affiliation":5,"role":38},"Jill Kolesar, PharmD, MS, FCCP","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":24,"email":44},"Laura Seegmiller","CONTACT","(319) 384-1494","champ-study@uiowa.edu",[46,62,79],{"facility":5,"status":47,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":53,"geoPoint":58,"contacts":59},"RECRUITING","Iowa City","Iowa","52242","United States","US",{"type":54,"coordinates":55},"Point",[56,57],-91.53017,41.66113,{"lat":57,"lon":56},[60,61],{"name":41,"role":42,"phone":43,"phoneExt":24,"email":44},{"name":37,"role":38,"phone":24,"phoneExt":24,"email":24},{"facility":63,"status":47,"city":64,"state":49,"zip":65,"country":51,"countryCode":52,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Cedar Valley Primary Care & Walk-In Clinic","Waterloo","50701",{"type":54,"coordinates":67},[68,69],-92.34296,42.49276,{"lat":69,"lon":68},[72,76],{"name":73,"role":42,"phone":74,"phoneExt":24,"email":75},"Sarah Larson, BSN, RN","319-888-8270","slarson@cvmspc.com",{"name":77,"role":78,"phone":24,"phoneExt":24,"email":24},"James Hoehns, PharmD, BCPS, FCCP","SUB_INVESTIGATOR",{"facility":80,"status":47,"city":64,"state":49,"zip":81,"country":51,"countryCode":52,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Greenwood Pharmacy and Compounding Center","50702",{"type":54,"coordinates":83},[68,69],{"lat":69,"lon":68},[86],{"name":87,"role":42,"phone":24,"phoneExt":24,"email":24},"Robert Nichols, PharmD, BCPS",{"type":89,"investigatorFullName":90,"investigatorTitle":91,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"SPONSOR_INVESTIGATOR","Jill Kolesar","Principal Investigator",[93],{"name":94,"class":95},"Eli Lilly and Company","INDUSTRY","100636983","champ-lung-cancer-screening-program-100636983",false,"NCT07572773","CHAMP Lung Cancer Screening Program","CHAMP: Community Health Assessment and Monitoring in the Pharmacy. Assessing the Impact of a Community Pharmacist Lung Cancer Screening (LCS) Program","CHAMP","Inclusion Criteria:\n\n* aged 50-77\n* smoking pack-year history of ≥ 20 years\n* current smoker or quit smoking 15 or less years ago\n* ability to understand and willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n* self-report of lung cancer screening in the last 12 months\n* psychiatric illness\u002Fsocial situations that would limit compliance with study requirements","ALL","50 Years","77 Years",{"count":108,"type":109},300,"ESTIMATED","INTERVENTIONAL",[112],"NA","The U.S. Preventive Services Task Force recommends annual lung cancer screening (LCS) with low-dose CT for adults aged 50-80 with a ≥20 pack-year smoking history who currently smoke or quit within the past 15 years. Despite insurance coverage, only 17% of eligible Iowans were screened in 2024. Barriers include the complexity of screening and competing demands in primary care. To address these challenges, investigators propose a two-part intervention: a blood-based screening test to simplify LCS and a community pharmacist-led referral program integrated into routine pharmacy care.\n\nEligible patients will be identified at Greenwood Pharmacy in Waterloo, Iowa. Interested individuals will be consented by a pharmacist and engaged in shared decision-making about LCS. Participants may decline screening, complete the DELFI Diagnostics FirstLook lung cancer screening blood test, or pursue CT screening through their primary care physician. Those choosing the blood test will be referred to Cedar Valley Family Medicine. Patients with a positive result will complete a standard shared decision-making visit with their PCP and, if appropriate, undergo confirmatory CT imaging. Patients with a negative result will enter a screening cohort and be re-screened annually for an additional year.",[115,116],"Lung Cancer","Early Lung Cancer Detection",[118,119,120,121,122],"lung cancer","early lung cancer detection","lung cancer screening","community pharmacy intervention","pharmacy cancer screening","2026-06-12",{"date":125,"type":126},"2026-06-16","ACTUAL",{"date":123,"type":126},{"date":129,"type":109},"2028-06",{"name":90,"class":6},3]